AstraZeneca's Summit Therapeutics Investment Looks Like Win-Win for Both — Market Talk

AstraZeneca's $2 billion investment in Summit Therapeutics works for both companies, UBS analysts say in a research note. For Summit, this is potentially a best-case scenario that provides external validation of its lead drug candidate ivonescimab and gives it funding to go through pivotal study re…